CA2663091A1 — Modulators of interleukin-1 receptor-associated kinase
Assigned to Biogen MA Inc · Expires 2008-03-13 · 18y expired
What this patent protects
The present invention relates to modulators of IRAK kinase and provides compositions comprising such modulators, as well as methods therewith for treating conditions or diseases mediated by or associated with IRAK kinase, such as rheumatoid arthitis, multiple sclerosis, sepsis, o…
USPTO Abstract
The present invention relates to modulators of IRAK kinase and provides compositions comprising such modulators, as well as methods therewith for treating conditions or diseases mediated by or associated with IRAK kinase, such as rheumatoid arthitis, multiple sclerosis, sepsis, osteoarthrites, inflammatory bowel disease, osteoporosis, myasthenia gravis, stroke, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, psoriasis, cardiac contractile dysfunction, type I diabetes, type II diabetes, familial cold autoinf lammatory syndrome, severe bacterial infections, allergic disease, cancer, psoriasis, asthma, or graft rejection.
Drugs covered by this patent
- Copiktra (DUVELISIB) · Secura
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.